FDG-PET/CT in oncology;FDG-PET/CT in der onkologie

NuklearMedizin

Volumn 46, Issue 6, 2007, Pages 291-301

  Krause, B J ^a,h   Beyer, T ^b   Bockisch, A ^b   Delbeke, D ^c   Kotzerke, J ^d   Minkov, V ^e   Reiser, M ^f   Willich, N ^g   Bartenstein, P ⁱ   Baum, R P ⁱ   Burchert, W ⁱ   Haberkorn, U ⁱ   Kluge, R ⁱ   Knapp, W H ⁱ   Kuwert, T ⁱ   Nitzsche, E ⁱ   Reske, S N ⁱ   Reuland, P ⁱ   Schicha, H ⁱ   Schober, O ⁱ   Schwaiger, M ⁱ   Stabell, U ⁱ   Van Den Hoff, J ⁱ   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ NONE

Author keywords

FDG; Guideline; Oncology; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE;

CANCER DIAGNOSIS; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DYSPLASIA; GERMANY; HUMAN; HYPERPLASIA; ISCHEMIA; LEGAL ASPECT; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REVIEW; TUMOR;

EID: 37349114413     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-282     Document Type: Review

References (50)

1. Adolf E, Chatterjee T, Ince H, et al. Kontrastmittel-induzierte Nephropathie. Klinik und Prävention. Dtsch Med Wochenschr 2005; 130: 2391-2396.
2. Allen-Auerbach M, Yeom K, Park J, Phelps M, Czernin J. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med 2006; 47: 298-301.
3. Antoch G, Freudenberg LS, Egelhof T et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002; 43: 1339-1342.
4. 18F-FDG PET/CT. J Nucl Med 2004; 45: 56S-65S.
5. Antoch G, Vogt FM, Freudneberg LS, et al. Whole-body dual-modality PET/CT and whol-body MRI for tumor staging in oncology. JAMA 2003; 290: 3199-3206.
6. Berthelsen A, Holm S, Loft A, Klausen T, Andersen F, Højgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005; 32: 1167-1175.
7. Beyer T, Townsend DW, Brun T et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379.
8. 18F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows. Eur J Nucl Med Mol Imaging 2005; 32: 1429-1439.
9. Beyer T, Townsend DW. Putting 'clear' into nuclear medicine: a decade of PET/CT development. Eur J Nucl Med Mol Imaging 2006; 33: 857-861.
10. Blodegtt TD, Meltzer CC, Townsend DW. PET/CT: Form and Function. Radiology 2007, 242: 360-385.
11. Brix G, Beyer T. PET/CT: dose-escalated image fusion? Nuklearmedizin 2005;44 (Suppl 1): S51-S57.
12. 18F-FDG PET/CT examinations. J Nucl Med 2005; 46: 608-613.
13. Bundesamt für Strahlenschutz. Bekanntmachung der diagnostischen Referenzwerte für radiologische und nuklearmedizinische Untersuchungen. Bundesanzeiger 2003; 143: 17503-17504.
14. Cohade C, Osman M, Nakamoto Y et al. Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med 2003; 44: 412-416.
15. Coleman RE, Delbeke D, Guiberteau MJ et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med 2005; 46: 1225-1239.
16. Czernin J. PET/CT: imaging structure and function. J Nucl Med 2004; 45 (suppl 1): 1S-103S.
17. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J Nucl Med 2007; 48 (Suppl 1): 78S-88S.
18. 18F-FDG PET/CT 1.0. J Nucl Med 2006; 47: 885-895.
19. Dizendorf E, Hany TF, Buck A et al. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 2003; 44: 732-738.
20. Erdi YE, Nehmeh SA, Pan T, et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med 2004; 45: 1287-1292.
21. Franzius C, Schober O. Is PET/CT necessary in pediatric oncology? For. Eur J Nucl Med Mol Imaging 2006; 33: 960-965.
22. Gambhir SS, Czernin J, Schwimmer J et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42 (Suppl): 1S-93S.
23. Goerres GW, von Schulthess GK, Steinert HC. Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med 2004; 45 (suppl 1): 66S-71S.
24. Grosu AL, Piert M, Weber WA et al. Positron emission tomography for radiation treatment planning. Strahlenther Onckol 2005; 181: 483-499.
25. Halpern BS, Dahlbom M, Auerbach MA, et al. Optimizing imaging protocols for overweight and obese patients: A lutetium orthosolicate PET/CT study. J Nucl Med 2005; 46: 603-607.
26. Hausegger K, Reinprecht P, Kau T, Igerc I, Lind P. Clinical experience with a commercially available negative oral contrast medium in PET/CT. Fortschr Roentgenstr 2005; 177: 796-799.
27. 18F-FDG. J Nucl Med 2002; 43: 210-214.
28. Jaskowiak CJ, Bianco JA, Perlamn SB, Fine JP. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 2005; 46: 424-428.
29. 18FDG-PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005; 46: 587-595.
30. Kinahan PE, Hasegawa BH, Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 2003; 33: 166-179.
31. Kuehl H, Antoch G. How much CT do we need for PET/CT? A radiologist's perspective. Nuklearmedizin 2005; 44 (suppl 1): S24-S31.
32. Nakamoto Y, Chin BB, Kraitchman DL et al. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 2003; 227: 817-824.
33. 18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 2006; 81: 209-225.
34. Noßke D, Minkov V, Brix G. Festlegung und Anwendung diagnostischer Referenzwerte für nuklearmedizinische Untersuchungen in Deutschland. Nuklearmedizin 2004; 3: 79-84.
35. Osman MM, Cohade C, Nakamoto Y et al. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 2003; 44: 240-243.
36. Pan T, Malawi O, Nehmeh S et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 2005; 49: 1481-1487.
37. 18F-FDG: standardized uptake values in normal tissues. J Nucl Med 2004; 45: 784-788.
38. PET-CT Consensus Conference; SNMTS; American Society of Radiologic Technologists (ASRT). Fusion imaging: a new type of technologist for a new type of technology. J Nucl Med Technol 2002; 30: 201-204.
39. Pietrzyk U. Does PET/CT render software fusion obsolete? Nuklearmedizin 2005; 44 (suppl 1): S13-S17.
40. Richtlinie "Fachkunde und Kenntnisse im Strahlenschutz bei dem Betrieb von Röntgeneinrichtungen in der Heilkunde oder Zahnheilkunde vom 22. Dezember 2005". GMBI 2006; 22: 413.
41. Strahlenschutz in der Medizin. Richtlinie nach der Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung - StrlSchV) vom 24. Juni 2002. Bundesanzeiger 2002; 207a.
42. Strahlenschutzkommission. Strahlenschutz bei der Anwendung der Positronen-Emissions-Tomographie/Computer-Tomographie (PET/CT). Stellungnahme vom 08./09.12.2005. http://www.ssk.de/werke/kurzinfo/2005/ssk0513.htm
43. Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med 2003; 33: 193-204.
44. Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung - StrlSchV) vom 20. Juli 2001 (BGBl. I S. 1714, 2002 I S. 1459), zuletzt geändert durch Artikel 2, § 3 Abs. 31 des Gesetzes vom 1. September 2005. BGBl. I S. 2618, 2658.
45. Verordnung über den Schutz vor Schäden durch Röntgenstrahlung (Röntgenverordnung - RöV) vom 8. Januar 1987 (BGBl. I S. 114) in der Fassung der Bekanntmachung vom 30. April 2003. BGBl. I S. 604.
46. Verordnung zur Änderung der Verordnung über radioaktive oder mit ionisierenden Strahlen behandelte Arzneimittel vom 22.12.2006. BGBI 2006 I S. 3462.
47. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 2004; 45 (suppl 1): S82-S95.
48. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24: 3282-3292.
49. Yau YY, Chan WS, Tam YM et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med 2005; 46: 283-291.
50. 18F-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.